Posted by Michael Wonder on 14 May 2018
The Scottish Medicines Consortium accepts use of Kyntheum (brodalumab) for eligible patients with moderate-to-severe plaque psoriasis
11 May 2018 - The SMC has issued advice accepting brodalumab 210 mg for restricted use within NHS Scotland.
Following a successful resubmission, the SMC has accepted brodalumab for the treatment of moderate-to-severe plaque psoriasis in adult patients who have not responded to standard systemic therapies, or who are unable to take them.
This advice is contingent on the continued provision of a Patient Access Scheme, under which brodalumab is offered at a confidential discount to the NHS, or a list price that is equivalent or lower. Following this assessment, brodalumab will be available to appropriate patients on the NHS in Scotland.
